Wegovy Pill:
Coupled with total prescriptions for Q1 2026 of around 1.3 million and now more than 2 million since launch, it marks the strongest-ever GLP-1 volume launch in the US. Q1 2026 sales for Wegovy® pill reached DKK 2,256 million, impacted by pre-launch pipeline fill with wholesalers and telehealth partners.
Reuters: Novo said its adjusted operating profit was 32.86 billion Danish crowns ($5.16 billion) in the first quarter against a mean forecast of 28.74 billion according to a company-compiled poll.
solid bevegelse her
Call om litt under 1 time, blir spenndene å se om de greier å snakke kursen nedover igjen 
Da kommer det mer data fra denne neste mnd på ADA. Fase 2 planlagt å starte nå i Q2
Ellers spennende kommentarer blant analytikerne når det kommer til Wegovy pill:
“We have been very impressed by the willingness of users to self-pay and how fast the pills have caught on,” said Jyske Bank analyst Henrik Hallengreen Laustsen, who now sees pills taking 35-40% of the market, above earlier forecasts of 15-20%.
“I don’t think it is going to cannibalise patients who are already happy with an injectable,” said BMO Capital analyst Evan Seigerman. “It is another way for both Novo and Lilly to get to patients who don’t want an injectable.”
"I alt foretrækker 82 pct. af de adspurgte læger Novos vægttabspille, skriver Michael Shah, der dog tager forbehold for, at lægernes kendskab til Foundayo har været begrænset af, at Lilly først for alvor satte skub i markedsføringen af pillen i anden halvdel af april.
Ifølge Bloombergs medicinalanalytiker peger undersøgelsen i øvrigt på, at pillebehandling til vægttab kan blive foretrukket som førstebehandling på grund af lave priser, ligesom de vil være egnet til vedligeholdelsesbehandling af vægttab.
På sigt vurderes pillerne at tage cirka halvdelen af markedet målt i volumen, skriver Michael Shah.
Leger vet utmerket godt hva virkestoffet er. Og det har vært på markedet i pilleform i en god del år nå under navnet Rybelsus (14 mg semaglutid-tablett for diabetes). Ganske mange sånne tabletter som har blitt skrevet og ut tatt, uten nevneverdige problemer. Så hvorfor skulle da man da sette nye pasienter på Foundayo, som er et ganske uskrevet blad (enn så lenge?). Er ingenting Oral W ikke klarer som Foundayo klarer. Bortsett fra potensielle leverskader, da.
Lurer på når LLY kommer frem til at måten Foundayo får markedsandel er å kutte prisen i 2? Det kommer til å skje. Men når?
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
2026-05-12 08:00:00
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1
Participants treated with the higher dose of Wegovy ® reached weight loss goals faster as compared to semaglutide 2.4 mg1
The majority of the weight loss comes from losing body fat: 84% of weight loss with Wegovy ® (semaglutide 2.4 and 7.2 mg) can be attributed to reductions in fat mass, while preserving muscle function and improving muscle health2
Bagsværd, Denmark, 12 May 2026 – Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the weight loss drug Wegovy ® is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment1.
Moreover, a separate STEP UP sub-analysis presented at ECO shows that most of the weight loss with Wegovy ® was coming from body fat, and most of the muscle mass was kept2.
The STEP UP trial in people with obesity tested the higher dose of semaglutide (7.2 mg) against the 2.4 mg dose and placebo over 72 weeks in over 1,400 adults living with obesity without type 2 diabetes3. The results were striking. On average, people taking the 7.2 mg dose lost 21% of their total body weight – the equivalent of around 23 kg for the average person in the trial who weighed 113 kg before starting treatment with semaglutide3. People on the 2.4 mg dose lost about 17.5% within 72 weeks, while those on the placebo lost 2.4%3. The 21% weight loss with semaglutide 7.2 mg was achieved with a safety and tolerability profile consistent with the 2.4 mg semaglutide dose3.
A new analysis has revealed insights into how fast and how much weight loss people who respond differently can expect, and the findings are presented at ECO. ‘Early responders’ were identified as people who lost 15% or more of their body weight within just the first 24 weeks (about 6 months) of treatment1. About 1 in 4 people (27%) taking the 7.2 mg dose of Wegovy ® had an early response, compared with about 1 in 5 (21%) on the 2.4 mg dose and 3% on placebo1. The early responder group lost 27.7% of their body weight at week 721.
STEP UP weight-loss results 1,3
Semaglutide 7.2 mg Semaglutide 2.4 mg Placebo STEP UP primary results Average weight loss % across all groups 20.7% 17.5% 2.4% STEP UP sub-analysis Average weight loss % in early responders (≥15% loss by week 24) 27.7% (in 26.9% of participants) 24.8% (in 20.9% of participants) - Average weight loss in Responders (excluding early responders) 15.4% 13.2% - “Obesity as a chronic disease demands lifelong, holistic treatment. Early weight loss may indicate who is likely to achieve the most weight loss from semaglutide – but it is important to highlight that those without an ‘early’ treatment response still experience a substantial and clinically meaningful weight loss. These new insights from the STEP UP sub-analysis presented at ECO can help healthcare professionals with managing expatiations and setting goals with their patients when initiating obesity medications and potentially support long-term persistence to treatments,” said Dr Dror Dicker, associate clinical professor of Internal Medicine at The Faculty of Medicine and Health Sciences, Tel-Aviv University, Israel.
Improved muscle health
Another secondary analysis from a sub-population (55 participants) in the STEP UP trial studied body scan images (MRI) showing that 84% of the lost weight with semaglutide (2.4 and 7.2 mg) was due to a reduction in fat mass2. The abdominal visceral fat was reduced by over 30% with semaglutide2. Muscle mass was reduced by only 10% compared to baseline with semaglutide, and importantly, this was accompanied by improved muscle health, as assessed by the amount of muscle fat2. Both visceral and muscle fat are highly associated with the risk of cardiometabolic complications4-6. This means the drug was highly effective at specifically targeting fat in different body depots. Importantly, participants taking semaglutide maintained their functional muscle strength, even as they lost significant weight2. Muscle function was measured using a 30-second sit-to-stand test, which showed the same functional muscle strength in both the semaglutide and placebo groups before and after treatment2. Together, these results underscore the healthy improvements seen with semaglutide in body composition and muscle function2."The analyses from STEP UP presented at ECO are really promising, further highlighting the potential of the higher dose of Wegovy® to achieve substantial weight loss. Importantly, for individuals focused on losing weight, the goal is often to reduce fat rather than muscle mass. These studies show that weight loss with Wegovy® is predominantly driven by reductions in fat, while muscle function is preserved. This is great news for people living with obesity,” said Emil Kongshøj Larsen, executive vice president and head of International Operations at Novo Nordisk.
The results of the STEP UP sub-analysis of semaglutide’s improvement of body composition have been submitted for publication to a scientific journal.
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
2026-05-12 12:25:00
- Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1.
- Substantial weight loss was consistent across all menopausal stages, as well as major reductions in waist circumference, a key indicator of metabolic health1.
- Women taking Wegovy® had an average 42–45% lower risk of migraine starting six months after initiation, and a 25% lower risk of depression, compared with menopausal hormone therapy alone2.
Bagsværd, Denmark, 12 May 2026 – Novo Nordisk today announced data demonstrating that Wegovy® (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond1. The menopausal stages are perimenopause (the transition phase), menopause and postmenopause (after menopause).
The findings are based on the STEP UP clinical weight management trial, the landmark SELECT clinical cardiovascular trial and one large-scale real-world evidence study, all presented at the European Congress on Obesity (ECO) 2026 in Istanbul, Türkiye1-3. The studies show that when women with obesity lose weight with semaglutide, they improve their body composition with reduced waist circumference, indicative of less visceral fat, and they also reduce their risk of heart attacks and strokes while improving their quality of life, from migraine burden to depression and menopause symptoms1-3.
Nearly one in five women worldwide are now living with obesity, and the burden intensifies during the menopause years, when hormonal changes drive weight gain, redistribute fat to the abdomen, and increase cardiometabolic risk4-6. During menopause years, women’s risk of heart attack rises notably and to the same level of men’s cardiovascular risk7-9. Cardiovascular disease remains the leading cause of death in women worldwide, claiming more lives than all cancers combined10. Yet women’s cardiovascular symptoms are frequently dismissed or misdiagnosed, and women remain underrepresented in heart disease research7.
"For women with obesity, hormonal changes during menopause can drive weight gain and increase the risk of a heart attack,” said Mette Thomsen, group vice president and head of Global Medical Affairs at Novo Nordisk. “New clinical and real-world data presented at ECO demonstrate that effective weight management with semaglutide around menopause addresses medical complications of obesity, such as heart disease and metabolic dysfunction. But it can also help address daily burdens such as migraine, depression and menopause-related challenges. We are excited to share new insights that may benefit the many women living with obesity.” Weight loss and heart health data 1,3
In a post-hoc analysis of the STEP UP trial, premenopausal women with obesity lost an average of 22.6%* of their body weight on once-weekly high-dose Wegovy® (semaglutide 7.2 mg) with over 4 in 10 (41.4%) achieving exceptional 25% or more weight loss, compared with placebo. Perimenopausal and postmenopausal women achieved weight loss of 19.7% and 19.8%, respectively*. By the end of the trial (week 72), nearly half of women in all groups had shifted from obesity categories (body mass index ≥30 kg/m2) to the overweight (body mass index ≥25 kg/m2) or normal range weight categories (body mass index 18.5-24.9 kg/m2). The average waist circumference reduction was 17.5%, 15.6% and 15.3% in pre, peri, and postmenopausal women, respectively, indicating major loss of dangerous visceral fat.These findings indicate that treatment with semaglutide consistently benefits women with significant weight loss throughout all life stages and that early treatment, before the menopause transition begins, could lead to additional weight loss.
Average weight loss and waist circumference reduction at 72 weeks for women taking
semaglutide 7.2 mg in the STEP UP trial
Menopausal stage Weight loss* Waist circumference reduction*
Premenopause 22.6% 17.5%
Perimenopause 19.7% 15.6%
Postmenopause 19.8% 15.3%
- Treatment effect if all people adhered to treatment
In a post-hoc analysis of the SELECT trial, perimenopausal and postmenopausal women with obesity and heart disease experienced meaningful risk reductions in heart attacks, strokes and cardiovascular death. The results were consistent with the overall SELECT trial findings and showed a numerically larger risk reduction in the perimenopausal women (42% lower risk compared to placebo) compared to the postmenopausal women (13% lower risk compared to placebo), although the difference between the groups was not statistically significant. These findings suggest that semaglutide can lower the cardiovascular risks significantly in women with obesity going through menopause, regardless of their menopausal stage.
“Menopause, associated weight gain and unwanted changes in cardiometabolic markers can significantly impact long-term health and well-being of women. Still, they remain one of the most neglected areas in obesity research,” said Dr Emilia Huvinen, Gynaecologist researcher and associate professor at the University of Helsinki. “Whether we look at cardiovascular outcomes or weight loss across menopausal stages, semaglutide appears to offer meaningful benefits for women with obesity that extend well beyond weight loss alone.”
Må nesten tillate meg å komme med en liten anekdotisk observasjon.
En slektning har begynte på Wegovy tidligere i år, og hen hadde etter mange år slitt med overvekt. Med hjelp av Wegvovy hadde hen fått den hjelpen hen trengte for å tro på at det var mulig. Gikk vel ned 8 kg på første 6 ukene, selv om det var med oppstartsdosen. Så det var virkelig en gamechanger etter en lang tung periode i dobbelt forstand.
NB: Og for alle de som tenker at det bare er å skjerpe seg å redusere matinntak og eller øke aktiviteten så husk at veldig mange av de med stor overvekt kommer i den situasjonen ut fra en mix av problemer av mental eller fysisk art. Og når du først er der, er det ikke nødvendigvis så enkelt å komme seg ut av det uten hjelp.
Tanker om dette @WernerVonHaussenberg ?
Wegovy 7,2 mg bør være en sterk utfordrer til Zepbound. Og Wegovy pillen er overlegen Foundayo (så langt). Har Novo det som trengs nå for å ta tilbake markedsandelene?
Litt mer bivirkninger. Men efficacy + leger & publikums kjennskap til medikamentet teller i positiv retning. Pillen får nok drahjelp av de millioner at tablettene som allerede er tatt i form av Rybelsus, og 7,2 mg dosen får drahjelp av millionene av sprøytestikk allerede satt med 2,4 mg.
7,2 mg subkutant og oral sema pillen er nok det siste Novo klarer å melke ut av semaglutid, men det kan jo fort vare en stund. Novo har sikkert fortsatt brutal profitt pr. enhet med dagens priser, så jeg gjetter at bare Novo kommer ned i pris mot copy drugsene (som allerede er på markedet i enkelte land), så kan Novo fortsatt selge med (noe mindre) profitt.
I skrivende stund ser det ut til at 7,2 mg semaglutid koster $399 vs. 15 mg tirzepatide på $449 i US. Tror NVO må ned i pris for å få tilbake markedsandeler for LLY i subkutant-markedet.
Ikke slik jeg ser det.
Men nå kan de i hvertfall stoppe å miste markedsandeler, hvis de bare priser riktig. Og det er da noe i seg selv, er det ikke?
Så lenge de opprettholder sin andel av markedet og markedet utvides, slik man kan antyde at Wegovy pill gjør, så er jo det også noe 
Enig.
Men LLY har en Mercedes 123 STV og en Ford Pinto på markedet, og en Lambo Countach som snart lanseres.
NVO har en Peugoet 504 i div. varianter, nå også inkludert en de har strukket 30 cm i lengde, og en som de har skåret taket av for å lage cabriolet.
Jeg venter på at NVO skal få seg noen flere modeller, jeg.
I et voksende marked trenger man diverse modeller for å treffe flest mulig kunder.
504 er en fin bil det, men ikke alle som ønsker det heller.
Skal ikke kimse av 504 limo
Venter bare på at Pintoen skal bli påkjørt bakfra, jeg.
Og kanskje at noen vanlig folk skal prøve å kjøre lambo, bare for å finne ut at det ikke var helt deres greie.
Ønskeliste for NVO:
Datsun Sunny
Opel Manta
Audi Quattro
BMW 5-serie
Toyota Hilux
Settler for Sunny og 5-serie til å begynne med
Tirsdag presenterte vi på European Congress on Obesity norske data som viser hvordan nordmenn som betaler for Wegovy av egen lomme, bruker medisinen. De aller fleste velger mindre doser enn det som anbefales, og ikke får ønsket effekt som vises i kliniske studier. Jeg mener det er åpenbart at dette handler om økonomi, mener Hovland.
Hun mener også at når folk ikke bruker legemidlene slik de skal brukes, fratar man også fastlegene et verktøy når de skal hjelpe pasienter.
https://www.tv2.no/nyheter/slankegigant-overrasket-over-nordmenns-forbrukeratferd/18831185/
Er amerikanere mange som har prøvekjørt det de tror er denne før lansering. Viser seg at det er denne de har testet (egentlig bare en Mercedes 123):
https://www.tv2.no/broom/dette-er-egentlig-en-vw-boble-fra-1973/8749314/
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
2026-05-13 08:00:00
Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 clinical trial1.
Nearly eight in 10 people with poor physical function who took the Wegovy® pill almost doubled their ability to move, including bending over, standing comfortably and staying active, compared to placebo2.
The ORION indirect treatment comparison and the OPTIC patient preference studies, now published (abstract) at the European Congress on Obesity, demonstrated that Wegovy® pill provides greater weight loss than orforglipron and has lower odds of stopping medication due to side effects3-5.
Bagsvær d, Denmark, 13 May 2026 – Novo Nordisk today presented new sub-analyses from the phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 (ECO2026) in Istanbul, Türkiye, showing how well Wegovy® pill (oral semaglutide 25 mg) works in adults living with obesity compared with placebo1,2.
The new findings show that nearly one in three adults (28.8%) who responded early to the Wegovy® pill – meaning ≥10% weight loss by week 16 – achieved 13.2% weight loss by week 16 of treatment1. This group of Wegovy® pill early responders went on to achieve 21.6% weight loss by the end of the trial (week 64), while people who did not meet the ‘early response’ criteria still went on to achieve 11.5% weight loss1. This meant that both groups achieved clinically meaningful weight loss by the end of the trial1.
“It is important for patients and healthcare professionals to understand that there are differences in the early rapidity of weight loss following initiation of treatment with oral semaglutide 25 mg, and how this can signal the longer-term degree of weight loss that may be achieved," said Prof. W. Timothy Garvey, MD, Department of Nutrition Sciences, University of Alabama at Birmingham. "While the clear majority of patients can expect clinically significant weight loss, these data can be helpful in managing dose escalation, patient expectations and the achievement of treatment goals.”
In addition to substantial weight loss, a separate analysis of the OASIS 4 trial, also presented at ECO2026, showed that when taking Wegovy® pill, nearly eight in 10 people who had poor physical function achieved clinically meaningful changes in function scores (77.3% vs 42.9% in the placebo group)2. These scores assess aspects of physical function such as range of motion and stamina6. This group of people also achieved similar weight loss to that seen in the overall Wegovy® pill group2.
“The evidence base supporting the benefits of the Wegovy® pill continues to grow. In addition to offering unmatched weight-loss efficacy in an oral obesity treatment, the data now underscores the meaningful improvements people can see in their day-to-day lives. Things many may take for granted, like the ability to stand for a length of time or simply bending down, can all be impacted by excess weight,” said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. “These analyses of our trial data expand our understanding of the broader benefits of Wegovy® pill, while reaffirming its best-in-class efficacy, tolerability and safety profile.”
Data supporting the ORION and OPTIC analyses, also presented and published at ECO2026, showed that Wegovy® pill delivered greater weight loss and lower odds of treatment discontinuation due to side effects than orforglipron3,4. The ORION indirect treatment comparison showed that Wegovy® pill demonstrated significantly greater mean weight loss than orforglipron 36 mg, and orforglipron was associated with ~14 times higher odds of stopping medication due to gastrointestinal side effects3. In the OPTIC patient preference study, 84% of survey respondents favoured a treatment profile similar to Wegovy® pill compared with that of orforglipron4.
The data presented at ECO2026 reaffirm the primary results of the OASIS 4 trial, where adults with a body mass index (BMI) of ≥30 (or ≥27 with ≥1 weight-related complication) taking Wegovy® pill showed an average 17% weight loss compared with 2.7% in the placebo group, and a consistent safety profile with the GLP-1 receptor agonist treatment class7.